Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
Scroll Up
Scroll Down

Unified Laboratory Intelligence for Impurity Resolution Management
Bookmark and Share

ACD Labs

Maximizing the effective patent life of a marketed drug is one of the main priorities for researchers. According to a March 2010 article in Nature, the estimated average cost for pharmaceutical companies to bring a new chemical entity (NCE) to market is approximately 1.8 billion and requires 13.5 years on average. Identifying and characterizing an impurity in a couple of days less time can literally equate to a gain of a million dollars in net present value. Being able to do this repeatedly as impurities are encountered through the drug development and acceptance of a drug substance can shave weeks, or even months, off the time to market, increasing returns by millions of dollars.

Unified Laboratory Intelligence (ULI) is a category of R&D informatics that combines software, algorithmic tools, and databases to form a scalable platform for the collection and unification of chemical, structural, and analytical data. ULI accumulates information and knowledge from successive projects across different chemistry disciplines to create a one-to-many chemical intelligence-from-information ‘live’ cycle. With ULI, scientists can easily search and quickly retrieve ‘live’ data to gain and apply intelligence and insight that improves decision-making. 

Further Information

Related Content

€9m EU-project on Deep-Sea Organisms Started
The PharmaSea project will evaluate the potential of new bioactive compounds from marine organisms as novel drug leads or ingredients for nutrition or cosmetic applications.
Friday, February 15, 2013
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!